Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

Azithromycin eases RV-induced airway inflammation in lung allograft recipients

25 Nov 2019

It appears that human rhinovirus (RV) can infect both the upper and lower airway epithelial cells (AEC), which can lead to cell death and inflammation, according to a recent study, noting that prophylactic treatment with azithromycin can lessen these harmful responses.

RV infection brought about significant cytotoxicity in both large and small AEC and caused a similar apoptotic response in both regions. A significant increase in receptor expression occurred in the large AEC only after viral infection. Moreover, there was an increase in viral replication in both large and small AEC, but it was not significantly different.

Prophylactic treatment with azithromycin led to a reduction in viral replication and in the production of inflammatory cytokines following infection.

“Findings provide further support for the prophylactic prescription of azithromycin to minimize the impact of RV infection,” the investigators said.

This study obtained matched large and small AEC from five lung allograft recipients. Primary cultures were established, and monolayers were infected with RV1b over time with varying viral titre. The investigators then examined cell viability, receptor expression, viral copy number, apoptotic induction and inflammatory cytokine production at each region. Finally, they assessed the effect of azithromycin on viral replication, induction of apoptosis and inflammation.

“RV is a common upper and lower respiratory pathogen in lung allograft recipients causing respiratory tract exacerbation and contributing towards allograft dysfunction and long‐term lung decline,” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]